ArticleThe clinical respiratory journal2026
Stage III Lymph Node-Positive Non-Small-Cell Lung Cancer Patients With or Without Lymph Node Irradiation by Stereotactic Body Radiation Therapy: Propensity Score-Matched Analysis.
Article in The clinical respiratory journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeThis study compared the local control (LC) and survival of patients with stage III lymph node-positive non-small-cell lung cancer (NSCLC) who received lymph node irradiation (LNs R+) and those who did not (LNs R-).
methodsWe retrospectively reviewed patients with stage III LN-positive NSCLC who underwent stereotactic body radiotherapy (SBRT) with or without lymph node irradiation between January 2013 and December 2018. Using propensity score matching (PSM) analyses, we compared the rates of LC, progression-free survival (PFS), overall survival (OS), and acute/late toxicities between the two groups.
resultsWe retrospectively analyzed 201 patients, of whom 52 received LN irradiation and 149 did not. The median LC and OS were 59.7 months (95% CI: 51.1-62.9 months) and 36.3 months (95% CI: 32.6-40.0 months), respectively. After the PSM analysis, 52 patients were included in each group. The median LC (30.6 months and not reached, HR 1.296, 95% CI: 0.733-2.294, p = 0.371) and OS (30.3 months and 31.6 months, HR 0.969, 95% CI: 0.628-1.496, p = 0.887) were similar between the LN R+ group and the LN R- group. Total tumor size, tumor location, and biologic equivalent dose (BED) were independently associated with LC (p < 0.05). The incidences of acute radiation esophagitis (p = 0.006) and late pulmonary interstitial fibrosis (p = 0.046) were significantly higher in the LN R+ group than in the LN R- group.
conclusionsSBRT is safe and effective in stage III LN-positive NSCLC patients. Omitting elective nodal irradiation achieves comparable survival to irradiating involved lymph nodes while significantly reducing toxicity. These findings support the development of novel combination strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.